INS and Hypoglycemia: Insulin/dextrose treatment can be complicated by hypoglycaemia (serum glucose <4.0 mmol/L) in 6–21% of people following treatment.1, 2, 3, 4, 5, 6, 7 Hypoglycaemia poses significant risk to patients, including increased risk of seizures, neurological symptoms and cardiac instability, with associated morbidity and ultimately mortality.5